Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus
New York, Jan 7, 2026, 15:40 (EST) — Regular session Merck & Co (MRK.N) shares were down about 0.3% at $108.59 in afternoon trade on Wednesday after the drugmaker said it had completed its cash tender offer for Cidara Therapeutics (CDTX.O) and expected to finish the acquisition through a merger later in the day. The company said the deal will…